Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (5082)	12/7/2001 10:06:27 AM
From: Ian@SI	Respond to of 52153

RE PDLI / Zamyl: What am I missing? The following news "bites" seem to state that Zamyl missed its primary endpoint, yet PDLI intends to proceed with BLA!!! Are heads buried in the sand??? 06:55 ET Protein Design (PDLI) 40.57: Reports positive clinical results from the Phase III trial of its humanized antibody Zamyl in patients with acute myeloid leukemia. An initial review of the data by PDLI indicates that Zamyl increased the overall response rate to 43% in the Zamyl plus chemotherapy patients. Co currently anticipates completing the filing of a BLA in the second half of 2003. 08:58 ET Protein Design (PDLI) 40.57: -- Update -- Co states in this morning's press release on its Zamyl trial that further analysis that required the complete response to occur within 70 days of the initiation of therapy -- which was the prospectively defined primary endpoint of the trial -- did not demonstrate statistically significant differences between the two arms of the trial. PDLI shares trading at $39 in pre-market. 09:08 ET Protein Design (PDLI) 40.57: --Update-- CIBC World Markets believes Phase III Zamyl data will clearly support approval of Zamyl for the treatment of refractory/relapsed AML, despite the trial not achieving statistical significance; says Zamyl has twice the response rate of AHP's drug Mylotarg and a better safety profile.

To: Biomaven who wrote (5082)	12/7/2001 10:26:36 AM
From: quidditch	Respond to of 52153

Thank you, Peter. Note that, for the time being, it looks as though Avalon will be wrong on its short call for CORR, albeit that was a year or so ago. It also seems that institutions/BT investors will not be as forgiving for MLNM's deal price compared to AVIR/MEDI, where MEDI roared back next day--different fits, different outlooks. Chuckle on you and Harmon as ethics reign supreme on COR vs. CORR. Textbook lore that if if the buyer OR seller gets his symbol confused on the security he thought he was trading and the other gets it rights, tough luck for the one who had it wrong. If BOTH made a mistake, rescission could be had. quid

To: Biomaven who wrote (5082)	12/10/2001 11:14:50 AM
From: Harold Engstrom	Read Replies (1) \| Respond to of 52153

Peter, Rick, et al: was the BTRN news this morning a let-down? It looked pretty positive to me... can't understand how companies that are comparably underpowered command much higher share prices... H